靶向BAP1：间皮瘤的新范式
Targeting BAP1: a new paradigm for mesothelioma.
作者信息
Schunselaar L M, Zwart W, Baas P
机构信息
Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Department of Thoracic Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
出版信息
Lung Cancer. 2017 Jul;109:145-146. doi: 10.1016/j.lungcan.2017.03.005. Epub 2017 Mar 18.
New treatment strategies for malignant pleural mesothelioma (MPM) are important. BAP1 mutations are present in 47-67% of the MPM tumors, making this a good target for treatment. Multiple functions of BAP1 are investigated in the preclinical situation. Due to many functions of BAP1, the phenotypic effect of BAP1 is diverse. Preclinical data on inhibitors reversing these phenotypic effects are promising. However, the mechanism of BAP1 is not fully elucidated yet and further research about the mechanism and possible inhibitors is necessary.
恶性胸膜间皮瘤（MPM）的新治疗策略至关重要。47%至67%的MPM肿瘤存在BAP1突变，这使其成为一个良好的治疗靶点。在临床前研究中对BAP1的多种功能进行了研究。由于BAP1具有多种功能，其表型效应是多样的。关于抑制剂逆转这些表型效应的临床前数据很有前景。然而，BAP1的机制尚未完全阐明，有必要对其机制和可能的抑制剂进行进一步研究。
Zotero 插件